Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | LIPE | Q05469 | 4/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.44 |
| ▸ | MDH1 | P40925 | 1/20 | 0.43 |
| ▸ | MDH2 | P40926 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5714399 | 0.92 | LIPE (0.47) | TRPV1TRPA1LIPEBCHE | |
| SCHEMBL5714274 | 0.87 | TRPV1 (0.54) | TRPV1TRPA1 | |
| SCHEMBL6102430 | 0.86 | TRPV1 (0.48) | TRPV1TRPA1LIPEHIF1AEPAS1 | |
| SCHEMBL5714887 | 0.85 | LIPE (0.66) | LIPECYP3A4CYP2C9BCHE | |
| SCHEMBL5714185 | 0.83 | ALDH1A1 (0.53) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5715442 | 0.83 | SCN9A (0.38) | TRPV1TRPA1LIPE | |
| SCHEMBL5714308 | 0.83 | HIF1A (0.47) | TRPV1TRPA1LIPEHIF1AEPAS1 | |
| SCHEMBL5714100 | 0.82 | THRB (0.45) | CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL6102857 | 0.81 | HIF1A (0.59) | TRPV1TRPA1HIF1AEPAS1 | |
| SCHEMBL5714295 | 0.81 | KDM4E (0.43) | CYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | TRPV1 1597/4885TRPA1 2010/4885LIPE 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.